Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 41
Inquire Before Buying

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2017, provides an overview of the Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline landscape.

Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema) and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease and heart failure. Treatment includes thrombolytic and anticoagulants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Deep Vein Thrombosis (DVT) - Overview
Deep Vein Thrombosis (DVT) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Deep Vein Thrombosis (DVT) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development
3SBio Inc
Dong-A Socio Holdings Co Ltd
F. Hoffmann-La Roche Ltd
Generex Biotechnology Corp
GlycoMimetics Inc
Laboratorios Farmaceuticos Rovi SA
Deep Vein Thrombosis (DVT) - Drug Profiles
Antisense RNAi Oligonucleotide for Deep Vein Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-20201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enoxaparin sodium biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fondaparinux sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heparin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polysaccharide to Inhibit Factor X for Deep Vein Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uproleselan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Deep Vein Thrombosis (DVT) - Dormant Projects
Deep Vein Thrombosis (DVT) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Deep Vein Thrombosis (DVT) - Pipeline by 3SBio Inc, H2 2017
Deep Vein Thrombosis (DVT) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
Deep Vein Thrombosis (DVT) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Deep Vein Thrombosis (DVT) - Pipeline by Generex Biotechnology Corp, H2 2017
Deep Vein Thrombosis (DVT) - Pipeline by GlycoMimetics Inc, H2 2017
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi SA, H2 2017
Deep Vein Thrombosis (DVT) - Dormant Projects, H2 2017
Deep Vein Thrombosis (DVT) - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Deep Vein Thrombosis (DVT), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Fibrinogen Concentrates Market Research Report 2017
    Published: 21-Nov-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Fibrinogen Concentrates market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Fibrinogen Concentrates in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - Ch......
  • China Intravenous Immunoglobulin (IVIg) Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
    Published: 21-Nov-2017        Price: US 4480 Onwards        Pages: 123
    Intravenous Immunoglobulin, also called gamma globulin or antibodies, is a highly purified blood product preparation that is derived from large pools of plasma donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or "lot" of Intravenous Immunoglobulin. Scope of the Report: This report focuses on the Intravenous Immunoglobulin (IVIg) in China market, to split the market based on manufacturers, Regions (Province), type and application. ......
  • United States Anemia Therapeutics Market Report 2017
    Published: 21-Nov-2017        Price: US 3800 Onwards        Pages: 98
    In this report, the United States Anemia Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth rate......
  • Global Low Molecular Weight Heparin Sales Market Report 2017
    Published: 17-Nov-2017        Price: US 4000 Onwards        Pages: 117
    In this report, the global Low Molecular Weight Heparin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Low Molecular Weight Heparin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Eur......
  • China Fibrinogen Concentrate Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
    Published: 17-Nov-2017        Price: US 4480 Onwards        Pages: 118
    Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. Fibrinogen Concentrate is used as a medicine for blood disease. Fibrinogen concentrate is a preparation of coagulation factors prepared from pooled plasma. Also known as "fibrin glue" or "fibrin sealant", the majority of available formulations contain a mixture of pooled plasma-derived fibrinogen and the enzyme thrombin. Scope of the Report: This report focuses on the Fibrinog......
  • Global Low Molecular Weight Heparin Market Research Report 2011-2023
    Published: 17-Nov-2017        Price: US 2320 Onwards        Pages: 82
    Summary Low Molecular Weight Heparin (LMWHs) is derived from UFH (Unfractionated heparin) by such processes as chemical degradation, enzymatic depolymerisation and gamma-radiation cleavage. Natural heparin consists of molecular chains of varying lengths, or molecular weights. Chains of varying molecular weights, from 5000 to over 40,000 Daltons, make up polydisperse pharmaceutical-grade heparin. LMWHs, in contrast, consist of only short chains of polysaccharide. LMWHs are defined ......
  • Global Argatroban Sales Market Report 2017
    Published: 17-Nov-2017        Price: US 4000 Onwards        Pages: 100
    In this report, the global Argatroban market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Argatroban for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeas......
  • Global and China Heparin Sodium Market Research by Company, Type & Application 2013-2025
    Published: 16-Nov-2017        Price: US 2000 Onwards        Pages: 105
    Summary Market Segment as follows: By Type - Type 1 - Type 2 - Type 3 By Application - Treatment of Venous Thromboembolism - Complications of Pregnancy - Cardioversion of Atrial Fibrillation/Flutter By Company - Shenzhen Hepalink - Bioibérica - Nanjing King-friend - Pfizer - SPL - Dongcheng Biochemicals - Changzhou Qianhong Bio-pharma - Cha......
  • Hemophilia A - Pipeline Review, H2 2017
    Published: 14-Nov-2017        Price: US 2000 Onwards        Pages: 146
    Hemophilia A - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2017, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape. Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the l......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs